CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 84% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Capital Com Australia Pty Ltd Australia (Regulated by ASIC) Capital Com UK Limited Authorised and regulated by the Financial Conduct Authority (FCA) Capital Com SV Investments Limited Cyprus / EU (Regulated by CYSEC) Сlosed Joint Stock Company «FinTech Solutions» (Regulated by NBRB) Smart Forex Broker LLC Capital Com Stock and CFD Investing Ltd Seychelles (Regulated by FSA) Capital Com Online Investments Ltd (Regulated by SCB) Our Global Offices

Scan to Download iOS&Android APP

English العَرَبِيَّة Bahasa Indonesia Български Čeština Dansk Deutsch Eesti ελληνικά Español Français Hrvatski Italiano Latviešu Lietuvių Magyar Nederlands Polski Português Română Русский Slovenčina Slovenščina Suomi Svenska Tiếng Việt ไทย 简体中文 繁體中文
Also you can contact us: call +44 20 8089 7893 support@capital.com

Trade Asensus Surgical, Inc. - ASXC CFD

0.6683
7.64%
0.0442
Low: 0.6666
High: 0.7332
Market Trading Hours* (UTC) Opens on Thursday at 14:30

Mon - Fri: 14:30 - 21:00

  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
  • Ownership
Trading Conditions
Spread 0.0442
Long position overnight fee

Long position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.030779 %
Charges from borrowed part ($-1.23)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.030779%
Short position overnight fee

Short position overnight fee

Margin. Your investment $1,000.00
Overnight fee -0.013666 %
Charges from borrowed part ($-0.55)
Trade size with leverage ~ $5,000.00
Money from leverage ~ $4,000.00
Go to platform
-0.013666%
Overnight fee time 22:00 (UTC)
Min traded quantity 1
Currency USD
Margin 20%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Key Stats
Prev. Close* 0.7236
Open* 0.7328
1-Year Change* -4.83%
Day's Range* 0.6666 - 0.7332
52 wk Range 0.28-0.92
Average Volume (10 days) 2.00M
Average Volume (3 months) 25.13M
Market Cap 176.47M
P/E Ratio -100.00K
Shares Outstanding 236.84M
Revenue 7.10M
EPS -0.31
Dividend (Yield %) N/A
Beta 1.79
Next Earnings Date Feb 27, 2023

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Feb 8, 2023 0.6683 -0.0381 -5.39% 0.7064 0.7403 0.6583
Feb 7, 2023 0.7236 0.0678 10.34% 0.6558 0.7380 0.6483
Feb 6, 2023 0.6688 0.0803 13.64% 0.5885 0.6853 0.5885
Feb 3, 2023 0.7311 0.0070 0.97% 0.7241 0.7748 0.7181
Feb 2, 2023 0.7201 -0.0244 -3.28% 0.7445 0.7723 0.7167
Feb 1, 2023 0.7239 -0.0658 -8.33% 0.7897 0.7948 0.6683
Jan 31, 2023 0.7715 -0.0313 -3.90% 0.8028 0.8268 0.7680
Jan 30, 2023 0.7980 0.0200 2.57% 0.7780 0.8346 0.7780
Jan 27, 2023 0.7981 -0.0010 -0.13% 0.7991 0.8546 0.7580
Jan 26, 2023 0.8093 0.1239 18.08% 0.6854 0.8294 0.6683
Jan 25, 2023 0.6726 0.0043 0.64% 0.6683 0.6882 0.6583
Jan 24, 2023 0.6677 -0.0277 -3.98% 0.6954 0.6954 0.6611
Jan 23, 2023 0.6597 0.0114 1.76% 0.6483 0.7028 0.6483
Jan 20, 2023 0.6416 -0.0167 -2.54% 0.6583 0.6803 0.6284
Jan 19, 2023 0.6481 0.0024 0.37% 0.6457 0.6660 0.6084
Jan 18, 2023 0.5981 -0.0973 -13.99% 0.6954 0.7099 0.5885
Jan 17, 2023 0.6583 0.0424 6.88% 0.6159 0.7172 0.6084
Jan 13, 2023 0.5865 0.1246 26.98% 0.4619 0.5931 0.4588
Jan 12, 2023 0.4682 0.0252 5.69% 0.4430 0.4740 0.4291
Jan 11, 2023 0.4409 0.0039 0.89% 0.4370 0.4486 0.4370

Asensus Surgical, Inc. Events

Time (UTC) Country Event
No events scheduled
View all events
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total revenue 1.519 7.111 24.102 8.531 3.175 8.232
Revenue 1.519 7.111 24.102 8.531 3.175 8.232
Cost of Revenue, Total 1.069 6.727 16.171 20.731 5.166 11.096
Gross Profit 0.45 0.384 7.931 -12.2 -1.991 -2.864
Total Operating Expense 125.168 69.038 73.254 163.106 63.564 70.004
Selling/General/Admin. Expenses, Total 19.964 29.811 39.59 46.772 27.201 32.718
Research & Development 29.273 21.989 21.823 22.468 16.621 19.348
Depreciation / Amortization 6.967 7.858 10.868 10.301 10.801 11.254
Unusual Expense (Income) 67.413 0 -14.187 72.387 0.851 -2.847
Other Operating Expenses, Total 0.482 2.653 -1.011 -9.553 2.924 -1.565
Operating Income -123.649 -61.927 -49.152 -154.575 -60.389 -61.772
Interest Income (Expense), Net Non-Operating -1.889 -85.869 -17.128 -1.783 -0.32 -1.761
Other, Net 0.035 -0.3 1.126 -0.967 -0.119 1.296
Net Income Before Taxes -125.503 -148.096 -65.154 -157.325 -60.828 -62.237
Net Income After Taxes -119.98 -144.796 -61.777 -154.201 -59.312 -62.462
Net Income Before Extra. Items -119.98 -144.796 -61.777 -154.201 -59.312 -62.462
Net Income -119.98 -144.796 -61.777 -154.201 -59.312 -62.462
Income Available to Common Excl. Extra. Items -119.98 -144.796 -61.777 -154.201 -60.023 -62.462
Income Available to Common Incl. Extra. Items -119.98 -144.796 -61.777 -154.201 -60.023 -62.462
Diluted Net Income -119.98 -144.796 -61.777 -154.201 -60.023 -62.462
Diluted Weighted Average Shares 8.62962 11.4418 15.9384 17.737 70.809 226.96
Diluted EPS Excluding Extraordinary Items -13.9033 -12.655 -3.87599 -8.69375 -0.84767 -0.27521
Diluted Normalized EPS -8.8256 -12.655 -4.45456 -5.88489 -0.83986 -0.28337
Total Extraordinary Items 0
Total Adjustments to Net Income -0.711 0
Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022
Total revenue 2.083 1.102 2.571 2.476 1.066
Revenue 2.083 1.102 2.571 2.476 1.066
Cost of Revenue, Total 3.112 2.347 3.35 2.287 1.823
Gross Profit -1.029 -1.245 -0.779 0.189 -0.757
Total Operating Expense 17.496 14.339 20.009 18.16 20.019
Selling/General/Admin. Expenses, Total 7.045 7.41 9.108 9.155 9.252
Research & Development 4.215 4.089 4.469 6.575 6.428
Depreciation / Amortization 2.867 2.862 2.804 2.721 2.67
Unusual Expense (Income) 0 -2.847 0 0
Other Operating Expenses, Total 0.257 0.478 0.278 -2.578 -0.154
Operating Income -15.413 -13.237 -17.438 -15.684 -18.953
Interest Income (Expense), Net Non-Operating -1.936 0.074 0.057 0.044 0.055
Other, Net -0.029 -0.007 1.344 -0.012 -0.146
Net Income Before Taxes -17.378 -13.17 -16.037 -15.652 -19.044
Net Income After Taxes -17.34 -13.172 -16.069 -15.881 -19.128
Net Income Before Extra. Items -17.34 -13.172 -16.069 -15.881 -19.128
Net Income -17.34 -13.172 -16.069 -15.881 -19.128
Total Adjustments to Net Income 0 0 0 0
Income Available to Common Excl. Extra. Items -17.34 -13.172 -16.069 -15.881 -19.128
Income Available to Common Incl. Extra. Items -17.34 -13.172 -16.069 -15.881 -19.128
Diluted Net Income -17.34 -13.172 -16.069 -15.881 -19.128
Diluted Weighted Average Shares 204.992 233.25 234.337 234.94 235.892
Diluted EPS Excluding Extraordinary Items -0.08459 -0.05647 -0.06857 -0.0676 -0.08109
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -0.08459 -0.06441 -0.06857 -0.0676 -0.08109
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Total Current Assets 38.016 112.994 101.583 27.955 34.013 113.297
Cash and Short Term Investments 24.165 91.217 72.851 9.598 16.363 98.391
Cash & Equivalents 24.165 91.217 21.061 9.598 16.363 18.129
Total Receivables, Net 1.976 3.038 8.595 3.336 3.985 2.06
Accounts Receivable - Trade, Net 0.621 1.536 8.56 0.62 1.115 0.749
Total Inventory 7.883 10.817 10.941 10.653 10.034 8.634
Prepaid Expenses 3.992 7.922 9.196 4.368 3.631 3.255
Total Assets 176.249 250.251 239.307 74.779 78.258 186.473
Property/Plant/Equipment, Total - Net 5.772 6.67 6.337 7.006 11.542 16.319
Property/Plant/Equipment, Total - Gross 12.345 15.888 17.499 17.974 25.802 26.008
Accumulated Depreciation, Total -6.573 -9.218 -11.162 -10.968 -14.26 -9.689
Goodwill, Net 68.697 71.368 80.131 0
Intangibles, Net 53.01 52.638 50.463 31.066 22.267 9.892
Note Receivable - Long Term 0.266 0
Other Long Term Assets, Total 10.488 6.581 0.793 8.752 10.436 9.53
Total Current Liabilities 30.689 28.84 21.819 13.023 10.283 9.85
Accounts Payable 3.984 3.771 4.433 3.579 1.965 3.448
Accrued Expenses 7.883 10.379 9.228 8.553 6.301 5.859
Notes Payable/Short Term Debt 0 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 7.997 4.788 0 1.228 0
Other Current Liabilities, Total 10.825 9.902 8.158 0.891 0.789 0.543
Total Liabilities 58.379 71.403 70.786 19.244 16.689 17.227
Total Long Term Debt 4.995 8.385 28.937 0 1.587 0
Long Term Debt 4.995 8.385 28.937 0 1.587 0
Deferred Income Tax 10.397 8.389 4.72 1.392 0
Other Liabilities, Total 12.298 25.789 15.31 4.829 4.819 7.377
Total Equity 117.87 178.848 168.521 55.535 61.569 169.246
Common Stock 0.115 0.199 0.216 0.021 0.116 0.235
Additional Paid-In Capital 426.609 621.261 676.373 720.484 781.397 954.649
Retained Earnings (Accumulated Deficit) -302.844 -447.64 -509.406 -663.6 -722.912 -785.374
Treasury Stock - Common -0.241 0
Other Equity, Total -5.769 5.028 1.338 -1.37 2.968 -0.264
Total Liabilities & Shareholders’ Equity 176.249 250.251 239.307 74.779 78.258 186.473
Total Common Shares Outstanding 8.89867 15.3288 16.6413 20.6913 116.231 235.219
Short Term Investments 51.79 0 80.262
Redeemable Preferred Stock 0 0
Total Preferred Shares Outstanding 0
Other Current Assets, Total 0.957
Long Term Investments 37.435
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Total Current Assets 182.325 174.007 134.807 113.297 118.684
Cash and Short Term Investments 165.245 157.078 117.751 98.391 103.741
Cash & Equivalents 165.245 157.078 59.779 18.129 24.828
Total Receivables, Net 2.306 0.96 2.266 2.06 1.841
Accounts Receivable - Trade, Net 2.306 0.96 0.955 0.749 0.53
Total Inventory 11.181 12.523 11.954 8.634 9.141
Other Current Assets, Total 3.593 3.446 0.627 0.957 0.935
Total Assets 223.615 212.004 199.759 186.473 166.56
Property/Plant/Equipment, Total - Net 13.413 13.975 14.239 16.319 15.523
Intangibles, Net 18.591 15.943 12.82 9.892 7.009
Other Long Term Assets, Total 9.286 8.079 7.751 9.53 10.617
Total Current Liabilities 9.508 8.307 9.421 9.85 8.653
Accounts Payable 2.327 2.653 3.231 3.448 3.521
Accrued Expenses 3.83 4.868 5.512 5.859 4.599
Notes Payable/Short Term Debt 0 0 0 0 0
Current Port. of LT Debt/Capital Leases 2.459 0 0 0
Other Current Liabilities, Total 0.892 0.786 0.678 0.543 0.533
Total Liabilities 17.697 16.443 18.258 17.227 15.735
Total Long Term Debt 0.356 0 0 0 0
Long Term Debt 0.356 0 0 0
Other Liabilities, Total 7.833 8.136 8.837 7.377 7.082
Total Equity 205.918 195.561 181.501 169.246 150.825
Redeemable Preferred Stock 0 0 0 0 0
Common Stock 0.233 0.234 0.234 0.235 0.236
Additional Paid-In Capital 944.907 947.249 950.242 954.649 956.557
Retained Earnings (Accumulated Deficit) -740.252 -753.424 -769.493 -785.374 -804.502
Other Equity, Total 1.03 1.502 0.518 -0.264 -1.466
Total Liabilities & Shareholders’ Equity 223.615 212.004 199.759 186.473 166.56
Total Common Shares Outstanding 232.717 234.231 234.37 235.219 236.415
Total Preferred Shares Outstanding 0 0
Short Term Investments 57.972 80.262 78.913
Prepaid Expenses 2.209 3.255 3.026
Long Term Investments 30.142 37.435 14.727
  • Annual
  • Quarterly
2016 2017 2018 2019 2020 2021
Net income/Starting Line -119.98 -144.796 -61.777 -154.201 -59.312 -62.462
Cash From Operating Activities -52.386 -47.295 -48.493 -73.484 -46.675 -40.659
Cash From Operating Activities 1.942 2.486 2.42 2.166 2.898 2.857
Amortization 6.967 7.858 10.868 10.301 10.801 11.254
Deferred Taxes -5.562 -3.3 -3.377 -3.224 -1.516 0.225
Non-Cash Items 70.148 94.494 9.288 76.825 11.171 6.24
Cash Interest Paid 1.289 0.899 1.73 2.187 0 0
Changes in Working Capital -5.901 -4.037 -5.915 -5.351 -10.717 1.227
Cash From Investing Activities -1.361 5.509 -53.481 67.645 -0.003 -119.668
Capital Expenditures -1.361 -1.991 -0.77 -0.437 -0.003 -1.368
Cash From Financing Activities 49.943 104.371 26.452 -5.609 53.37 161.705
Financing Cash Flow Items -1.35 -7.349 -2.432 -0.499 -0.11 -1.063
Issuance (Retirement) of Stock, Net 58.195 112.058 15.682 26.315 50.665 162.768
Issuance (Retirement) of Debt, Net -6.902 -0.338 13.202 -31.425 2.815 0
Foreign Exchange Effects -0.055 0.431 -0.433 0.364 0.27 0.376
Net Change in Cash -3.859 63.016 -75.955 -11.084 6.962 1.754
Other Investing Cash Flow Items, Total 7.5 -52.711 68.082 0 -118.3
Cash Taxes Paid -0.17
Mar 2021 Jun 2021 Sep 2021 Dec 2021 Mar 2022
Net income/Starting Line -17.34 -30.512 -46.581 -62.462 -19.128
Cash From Operating Activities -10.237 -18.485 -27.487 -40.659 -15.943
Cash From Operating Activities 0.802 1.585 2.416 2.857 0.869
Amortization 2.867 5.729 8.533 11.254 2.67
Deferred Taxes -0.038 -0.036 -0.004 0.225 0.084
Non-Cash Items 4.146 3.785 5.867 6.24 2.303
Changes in Working Capital -0.674 0.964 2.282 1.227 -2.741
Cash From Investing Activities -0.395 -0.7 -89.07 -119.668 23.045
Capital Expenditures -0.395 -0.7 -0.838 -1.368 -0.246
Cash From Financing Activities 159.605 160.108 160.141 161.705 -0.336
Financing Cash Flow Items -0.214 -1.041 -1.058 -1.063 -0.348
Issuance (Retirement) of Stock, Net 159.819 161.149 161.199 162.768 0.012
Foreign Exchange Effects -0.108 -0.329 -0.181 0.376 -0.045
Net Change in Cash 148.865 140.594 43.403 1.754 6.721
Issuance (Retirement) of Debt, Net 0 0 0
Other Investing Cash Flow Items, Total -88.232 -118.3 23.291
Cash Interest Paid 0
Cash Taxes Paid -0.029
Investor Name Investor Type Percent Outstanding Shares Held Shares change Holdings Date Turnover Rating
The Vanguard Group, Inc. Investment Advisor/Hedge Fund 4.8268 11431792 575904 2022-09-30 LOW
BlackRock Institutional Trust Company, N.A. Investment Advisor 1.5426 3653424 -20584 2022-09-30 LOW
Millennium Management LLC Hedge Fund 1.1492 2721843 -2318995 2022-09-30 HIGH
Geode Capital Management, L.L.C. Investment Advisor/Hedge Fund 0.9254 2191771 4666 2022-09-30 LOW
GSA Capital Partners LLP Hedge Fund 0.4227 1001158 629411 2022-09-30 HIGH
Ergoteles Capital Hedge Fund 0.4087 967987 -75876 2022-09-30 HIGH
Fernando (Anthony C J) Individual Investor 0.3475 823117 0 2022-04-18
State Street Global Advisors (US) Investment Advisor/Hedge Fund 0.345 817129 0 2022-12-31 LOW
Susquehanna International Group, LLP Investment Advisor 0.308 729462 -243844 2022-09-30 LOW
Milne David Bruce Individual Investor 0.2617 619884 0 2022-04-18 LOW
UBS Financial Services, Inc. Investment Advisor 0.2491 590010 171230 2022-09-30 LOW
SV Health Investors, LLC Venture Capital 0.2154 510142 0 2022-09-30 MED
Northern Trust Investments, Inc. Investment Advisor/Hedge Fund 0.1753 415150 0 2022-09-30 LOW
Hsiao (Jane H) Individual Investor 0.1422 336895 0 2022-04-18
T. Rowe Price International Ltd Investment Advisor/Hedge Fund 0.125 296100 296100 2022-09-30 MED
DWS Investment Management Americas, Inc. Investment Advisor/Hedge Fund 0.1219 288600 0 2022-09-30 LOW
Morgan Stanley & Co. LLC Research Firm 0.1196 283376 -237674 2022-09-30 MED
Advisor Group, Inc Investment Advisor 0.0903 213840 22666 2022-09-30 LOW
Caption Management, LLC Hedge Fund 0.085 201243 0 2022-09-30 HIGH
Biffi (Andrea) Individual Investor 0.0843 199738 0 2022-04-18

Why choose Capital.com? Our numbers speak for themselves.

Capital.com Group
+500000+

Traders

93000+

Active clients monthly

$57000000+

Monthly investing volume

$31000000+

Withdrawn each month

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
  • 2:1
  • 5:1
  • 10:1
  • 20:1
Leverage
20:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long
Past performance is not a reliable indicator of future results
Profit/Loss

Asensus Surgical, Inc. Company profile

Asensus Surgical (ASXC) is a medical device company that engages in digitising the interface between the surgeon and the patient to improve minimally invasive surgery (MIS). 

Founded in 2006, Asensus is headquartered in Durham, North Carolina. It pioneers a new era of performance-guided surgery, using advanced capabilities, like machine vision, augmented intelligence, connectivity and robotics in laparoscopy. 

Asensus has built the foundation of Digital Laparoscopy with the help of its Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to address clinical, cognitive and economic shortcomings in surgery.

The Senhance Surgical System is a multi-port robotic system that provides enhanced control with surgeon eye-tracking camera control & 3D (three dimensional) HD (high definition) vision and enhances precision through tremor filtrations and robotic stabilisation. Additionally, surgeons can have enhanced focus during surgery through Asensus’s optimised ergonomics and the sense of touch (haptics). 

The surgical device that consists of a robotic instrument and a camera for laparoscopic procedures is considered to be the smallest instrument offered in robotics, leading to smaller incisions than traditional robotic surgery. Asensus’ Senhance ultrasonic system is an advanced energy device to deliver controlled energy to ligate and divide tissue.

Asensus Surgical previously developed the SPIDER device and the SurgiBot System. It changed its name from TransEnterix in February 2021. The company went public as TransEnterix in May 2014. It trades on the NYSE American under the ticker ‘ASXC’.

Industry: Medical Equipment, Supplies & Distribution (NEC)

1 Tw Alexander Drive
Suite 160
DURHAM
NORTH CAROLINA 27703
US

Income Statement

  • Annual
  • Quarterly

News

Stock market indicators and cash dollars

Markets look for guidance after Powell speech, eyeing US CPI: USD, S&P 500, DAX 40

Us equities try to build appetite to push higher after Powell acknowledges disinflation during his speech

12:34, 8 February 2023
The XRP coin on a gavel

Ripple/SEC Lawsuit: News And Update

Ripple and the US Securities and Exchange Commission are still awaiting a ruling

15:00, 7 February 2023
Gold outlook

Gold Price Forecast: Gold Loses Shine as USD and US Yields Edge Higher

Gold correcting lower on USD comeback. Eyes on Chair Powell to exacerbate Gold downside

12:41, 7 February 2023
Close-Up Of Paper Currency

Australian Dollar Outlook: AUD/USD bounces back as RBA hikes 25bps

AUS/USD bounces higher as RBA delivers its 9th rate hike

11:28, 7 February 2023
Japanese Yen Outlook

Japanese Yen Outlook: USD/JPY Edging Towards YTD Peak on BoJ Dove and US Yields

Japanese Yen underperforms with BoJ dove touted to be Governor Kuroda successor.

14:36, 6 February 2023

People also watch

XRP/USD

0.40 Price
-1.330% 1D Chg, %
Long position overnight fee -0.0500%
Short position overnight fee 0.0140%
Overnight fee time 22:00 (UTC)
Spread 0.00412

Natural Gas

2.47 Price
-6.170% 1D Chg, %
Long position overnight fee -0.1217%
Short position overnight fee 0.0860%
Overnight fee time 22:00 (UTC)
Spread 0.005

Oil - Crude

78.63 Price
+1.160% 1D Chg, %
Long position overnight fee -0.0163%
Short position overnight fee 0.0021%
Overnight fee time 22:00 (UTC)
Spread 0.03

US100

12,542.20 Price
-1.230% 1D Chg, %
Long position overnight fee -0.0192%
Short position overnight fee 0.0077%
Overnight fee time 22:00 (UTC)
Spread 1.8

Market analysis

Two €50 banknotes on a map of Europe

Euro forecast: Will EUR continue rising?

18:38, 8 February 2023
Close-up of a $20 banknote and gold bullion

Gold price forecast for 2023 and beyond: Will the dollar keep it down?

17:21, 8 February 2023
Signage outside the entrance of the Reserve Bank of Australia building in Sydney, Australia.

Projected Australia interest rate in 5 years: RBA determined to dampen persistent inflation

16:44, 8 February 2023

Still looking for a broker you can trust?

Join the 500.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading